Samsung Bioepis begins commercialization of Byooviz in Europe

South Korean biosimilar specialist Samsung Bioepis today announced that it has begun direct commercialization of Byooviz, a biosimilar to Lucentis (ranibizumab), in Europe.

Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen (Nasdaq: BIIB) back to Samsung Bioepis, and Byooviz will now be available as a Samsung Bioepis brand across multiple European countries. Lucentis is marketed by Swiss pharma majors Novartis (NOVN: VX) and Roche’s (ROG: SIX).

“This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with Epysqli (eculizumab) and the newly launched Obodence (denosumab) and Xbryk (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis. “We will work closely with payers and healthcare professionals to ensure seamless access to our biosimilar medicines for patients in need.”